However, clinical application of the EGFR-neutralizing drug cetuximab has shown that AREG expression/secretion levels can compensatorily increase in the patient’s cancer microenvironment, leading to drug resistance development and being a predictive marker for anti-EGFR treatment [11,13,32,33]. This evidence concerns the gene EGFR and cancer.